Liu Yuan-Hui, Tan Ning, Liu Yong, Ye Piao, He Yi-Ting, Ran Peng, Jiang Lei
Graduate School, Southern Medical University,Guangzhou 510515, China.
Email:
Zhonghua Xin Xue Guan Bing Za Zhi. 2013 Sep;41(9):740-3.
To investigate the relationship between hyperuricemia and contrast-induced nephropathy (CIN) in patients with chronic kidney disease (CKD) undergoing percutaneous coronary intervention (PCI).
A total of 446 consecutive patients with CKD undergoing PCI in Guangdong general hospital were enrolled in this study. Patients were divided into hyperuricemic group (n = 205) and normouricemic group (n = 241).Hyperuricemia was defined as serum uric acid > 420 µmol/L for male, > 357 µmol/L for female. CIN was defined as ≥ 44.2 µmol/L or ≥ 25% increase from baseline Serum creatinine within 48-72 hours after contrast medium exposure, and that was not attributable to other causes.In hospital incidences of CIN and the major adverse cardiac events were compared between the two groups. The relationship between the incidence of CIN and hyperuricemia was evaluated by multivariate logistic regression analysis.
CIN occurred in 16.6% (74/446) of patients, and incidence of CIN was significantly higher in the hyperuricemic group than in the normouricemic group [23.9% (49/446) vs. 10.4% (25/446) , P = 0.000]. Patients who developed CIN had higher in hospital mortality [14.9% (11/74) vs. 1.3% (5/372), P = 0.000]. Need for renal replacement therapy, acute heart failure, intra-aortic balloon pump use and the hypotension after PCI were significantly higher in the hyperuricemic group compared with normouricemic group (P < 0.01 or P < 0.05) . Multivariate analysis indicates that hyperuricemia (OR = 1.9, 95%CI:1.1-3.5, P = 0.037), age > 75 years (OR = 3.2, 95%CI:1.8-5.7, P = 0.000) , emergent PCI (OR = 2.9, 95%CI:1.6-5.1, P = 0.000) and anemia (OR = 2.1, 95%CI:1.2-3.8, P = 0.012) were predictors of CIN in patients with CKD.
Hyperuricemia is the independent risk predictor of CIN in patients with CKD undergoing PCI.
探讨慢性肾脏病(CKD)患者经皮冠状动脉介入治疗(PCI)后高尿酸血症与造影剂肾病(CIN)之间的关系。
本研究纳入了广东省总医院446例连续接受PCI的CKD患者。患者被分为高尿酸血症组(n = 205)和正常尿酸血症组(n = 241)。高尿酸血症定义为男性血清尿酸>420µmol/L,女性>357µmol/L。CIN定义为造影剂暴露后48 - 72小时内血清肌酐≥44.2µmol/L或较基线水平升高≥25%,且非其他原因所致。比较两组患者住院期间CIN和主要不良心脏事件的发生率。通过多因素logistic回归分析评估CIN发生率与高尿酸血症之间的关系。
446例患者中发生CIN的有16.6%(74/446),高尿酸血症组CIN发生率显著高于正常尿酸血症组[23.9%(49/205)对10.4%(25/241),P = 0.000]。发生CIN的患者住院死亡率更高[14.9%(11/74)对1.3%(5/372),P = 0.000]。高尿酸血症组患者PCI后肾脏替代治疗需求、急性心力衰竭、主动脉内球囊泵使用及低血压发生率均显著高于正常尿酸血症组(P < 0.01或P < 0.05)。多因素分析表明,高尿酸血症(OR = 1.9,95%CI:1.1 - 3.5,P = 0.037)、年龄> 75岁(OR = 3.2,95%CI:1.8 - 5.7,P = 0.000)、急诊PCI(OR = 2.9,95%CI:1.6 - 5.1,P = 0.000)及贫血(OR = 2.1,95%CI:1.2 - 3.8,P = 0.012)是CKD患者发生CIN的预测因素。
高尿酸血症是接受PCI的CKD患者发生CIN的独立风险预测因素。